Evidence Synthesis
GUFICBIO's quarterly earnings report for 55.38% reveals a significant acceleration in the company's gross margin, up from 15.71% previously.
This improvement in gross margin is attributed to a deceleration in revenue growth yoy, moving from .1% to .8%. The company's marginal operating leverage has also accelerated, rising from .8% to .71%. Furthermore, the eps surprise percent has accelerated, increasing from .22950001% to .83699995%.
By paying you agree to our Terms and Privacy Policy.